Effects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 58, Issue 7, 2003, Pages 602-607

  Currie, G P ^a   Syme Grant, N J ^a   McFarlane, L C ^a   Carey, F A ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Asthma therapy; Fluticasone; Inflammation; Salmeterol

Indexed keywords

BIOLOGICAL MARKER; EOSINOPHIL CATIONIC PROTEIN; FLUTICASONE; METHACHOLINE; NITRIC OXIDE; SALMETEROL;

ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFECT; DRY POWDER; EOSINOPHIL; EXHALATION; GEOMETRY; HUMAN; LOW DRUG DOSE; OPEN STUDY; PRIORITY JOURNAL; SPIROMETRY; SPUTUM ANALYSIS; STATISTICAL SIGNIFICANCE; STEROID THERAPY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; BIOLOGICAL MARKERS; BLOOD PROTEINS; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTOR AGENTS; BRONCHODILATOR AGENTS; BUDESONIDE; CHLOROFLUOROCARBONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EOSINOPHIL GRANULE PROTEINS; EOSINOPHILS; FORCED EXPIRATORY FLOW RATES; FORCED EXPIRATORY VOLUME; HUMANS; METHACHOLINE CHLORIDE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RIBONUCLEASES; SEVERITY OF ILLNESS INDEX; SPIROMETRY; SPUTUM; TREATMENT OUTCOME;

EID: 0038575311     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2003.00188.x     Document Type: Article

References (33)

1. The British Thoracic Society Guidelines on Asthma Management: 1995 Review and Position Statement. Thorax 1997;52(Suppl. 1):S1-S21.
2. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Publication No. 97-4051. Bethesda, MD: National Institutes of Health, 1997.
3. BOULET LP, TURCOTTE H, BROCHU A. Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission. Chest 1994;105:1024-1031.
4. VIGNOLA AM, CHANEZ P, CAMPBELL AM, et al. Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med 1998;157:403-409.
5. SONT JK, HAN J, van KRIEKEN JM, et al. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax 1996;51:496-502.
6. SONT JK, WILLEMS LN, BEL EH, VAN KRIEKEN JH, VANDENBROUCKE JP, STERK PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999;159:1043-1051.
7. ROBERTS JA, BRADDING P, BRITTEN KM, et al. The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J 1999;14:275-282.
8. CALHOUN WJ, HINTON KL, KRATZENBERG JJ. The effect of salmeterol on markers of airway inflammation following segmental allergen challenge. Am J Respir Crit Care Med 2001;163:881-886.
9. GARDINER PV, WARD C, BOOTH H, ALLISON A, HENDRICK DJ, WALTERS EH. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994;150:1006-1011.
10. LAZARUS SC, BOUSHEY HA, FAHY JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. J Am Med Assoc 2001;285:2583-2593.
11. KHARITONOV SA, CHUNG KF, EVANS D, O'CONNOR BJ, BARNES PJ. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med 1996;153:1773-1780.
12. American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995;152:1107-1136.
13. BEACH JR, YOUNG CL, AVERY AJ, et al. Measurement of airway responsiveness to methacholine: relative importance of the precision of drug delivery and the method of assessing response. Thorax 1993;48:239-243.
14. PIN I, GIBSON PG, KOLENDOWICZ R, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992;47:25-29.
15. LIM S, JATAKANON A, JOHN M, et al. Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med 1999;159:22-30.
16. HOLT S, SUDER A, WEATHERALL M, CHENG S, SHIRTCLIFFE P, BEASLEY R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Br Med J 2001;323:253-256.
17. POLOSA R, HOLGATE ST. Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma? Thorax 1997;52:919-923.
18. VAN DEN BERGE M, MEIJER RJ, KERSTJENS HA, et al. PC(20) adenosine 5′-monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine. Am J Respir Crit Care Med 2001;163:1546-1550.
19. GUSTAFSSON LE. Exhaled nitric oxide as a marker in asthma. Eur Respir J Suppl 1998;26:49S-52S.
20. JATAKANON A, KHARITONOV S, LIM S, BARNES PJ. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999;54:108-114.
21. WILSON AM, LIPWORTH BJ. Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma. Am J Med 2000;108:269-275.
22. WEVER AM, WEVER-HESS J, HENSGENS HE, HERMANS J. Serum eosinophil cationic protein (ECP) in chronic asthma. Relationship to spirometry, flow-volume curves, PC20, and exacerbations. Respir Med 1994;88:613-621.
23. FERGUSON AC, VAUGHAN R, BROWN H, CURTIS C. Evaluation of serum eosinophilic cationic protein as a marker of disease activity in chronic asthma. J Allergy Clin Immunol 1995;95:23-28.
24. BACCI E, CIANCHETTI S, RUOCCO L, et al. Comparison between eosinophilic markers in induced sputum and blood in asthmatic patients. Clin Exp Allergy 1998;28:1237-1243.
25. PIZZICHINI E, PIZZICHINI MM, EFTHIMIADIS A, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996;154:308-317.
26. LEUPPI JD, SALOME CM, JENKINS CR, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001;163:406-412.
27. PARAMESWARAN K, HARGREAVE FE. The use of sputum cell counts to evaluate asthma medications. Br J Clin Pharmacol 2001;52:121-128.
28. SPANEVELLO A, VIGNOLA AM, BONANNO A, CONFALONIERI M, CRIMI E, BRUSASCO V. Effect of methacholine challenge on cellular composition of sputum induction. Thorax 1999;54:37-39.
29. GREEN RH, BRIGHTLING CE, MCKENNA S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-1721.
30. JEFFERY PK, VENGE P, GIZYCKI MJ, EGEROD I, DAHL R, FAURSCHOU P. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 2002;20:1378-1385.
31. EICKELBERG O, ROTH M, LORX R, et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999;274:1005-1010.
32. AZIZ I, WILSON AM, LIPWORTH BJ. Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults. Chest 2000;118:1049-1058.
33. CURRIE GP, BATES CE, LEE DKC, LIPWORTH BJ. Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol 2003 (in press).